Journal of Radiotherapy

Research Article

Uterine Carcinosarcoma Confined to the Pelvis: A Retrospective Review and Outcome Analysis

Table 1

Patients’ characteristics in each group and their corresponding TLR (time to local recurrence), TTM (time to metastasis), and overall survival. To be included in range, patients have to have an event (such as local recurrence, distant metastasis, or death) in the corresponding category.


	Surgery alone,		Surgery and Chemo,		Surgery and RT,		Surgery, RT, and Chemo,

Age
Median	66		69		67		62
Range	(39–84)		(57–78)		(46–86)		(46–76)

		%		%		%		%

Stage
I	14	67	3	57	5	42	10	50
II	2	9	0	0	4	33	0	0
III	5	24	4	43	3	25	10	50
Surgery
TAH-BSO	1	5	2	29	3	25	2	10
TAH-BSO PLND	5	24	0	0	1	8	1	5
TAH-BSO PPLND	15	71	5	71	8	67	17	85

	(24%)		(0%)		(8%)		(30%)

Time to local recurrence
<6 mo.	2				0		0
≥6–12 mo.	1				1		2
>12–24 mo.	1				0		3
>24–36 mo.	1				0		0
>36 mo.	0				0		1
Median (years)	0.75				0.68		1.29
Range (years)	(0.18–2.44)						(0.67–3.24)
Unspecified mass(es)	2				0		2
Vaginal cuff	3				0		4
Lymph mode(s)	0				1		0

	(24%)		(14%)		(25%)		(25%)

Time to metastasis
<6 mo.	0		0		1		0
≥6–12 mo.	1		0		2		1
>12–24 mo.	1		1		0		3
>24–36 mo.	2		0		0		0
>36 mo.	0		0		0		1
Median (years)	1.42		1.96		0.76		1.24
Range (years)	(0.62–2.86)				(0.17–0.84)		(0.96–3.24)
Lung/pleural	3		0		3		1
Brain	0		1		2		0
Bowels	1		0		0		2
Soft tissue/muscle	2		0		0		3
Liver	0		0		0		1
Bladder	0		0		0		1
Lymph node(s)	0		0		0		1

Overall survival
Median (years)	2.28		2.3		4.8		3.3
Range (years)	(0.08–3.69)		(0.28–2.42)		(0.25–4.9)		(0.85–3.33)

Follow-up time
Median (years)	1.92		0.48		1.78		2.66
Range (years)	(0.07–10.35)		(0.28–3.65)		(0.25–6.27)		(0.84–7.12)